SIGA Technologies applies microbial genomics to the design and development of novel products that prevent and treat infectious diseases, as well as defend against biological warfare agents. With technology platforms in both vaccines and antibiotics, the company s platform technologies include a vaccine delivery system that activates the immune system at the body s mucosal surfaces in order to prevent infection at the earliest possible stage, a surface protein expression system for the cost-effective production of proteins, biothreat rapid response therapeutics that can be rapidly designed on demand for any biological pathogen and virus counterstrike capability technology that can be used to develop safe and effective antivirals by targeting the proteinases which are encoded within all viruses. SIGA Technologies is headquartered in New York.

J Burke Capital Partners

Poseidon Services Inc

Grais & Ellsworth

Golden Law Inc